E-Thesis 363 views
Assessing the impact of tablet manufacturing on the viability and functionality of the LAB4® probiotic consortium / MARTYN ALLEN
Swansea University Author: MARTYN ALLEN
DOI (Published version): 10.23889/SUthesis.62296
Abstract
As defined by the WHO, probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host (WHO, 2002). Commonly, the target site for probiotic bacteria is the gastrointestinal system, and in particular, the epithelial layer of the large and small intes...
| Published: |
Swansea
2022
|
|---|---|
| Institution: | Swansea University |
| Degree level: | Doctoral |
| Degree name: | EngD |
| Supervisor: | Li, Chenfeng ; Dettmer, Wulf ; |
| URI: | https://cronfa.swan.ac.uk/Record/cronfa62296 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
As defined by the WHO, probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host (WHO, 2002). Commonly, the target site for probiotic bacteria is the gastrointestinal system, and in particular, the epithelial layer of the large and small intestines. The oral delivery route is often preferred as a less-invasive, low cost and high patient compliant method. Previously, probiotics and other beneficial organisms were commonly delivered through liquid and semi-solid (i.e. yogurt, milk and other dairy) products - however, these have been shown to lack temporal stability and consumer acceptability. More recently, lyophilisation techniques have allowed freeze-dried probiotics to be included into solid dosage formats that include directly compressed tablets. Probiotic bacteria are often selected based on their ability to exert [often strain-specific] effects on the host - the functionality of which is often assessed as the native strain. Recent work has shown that the influence of exogenous stressors introduced during stages of manufacturing have the ability to affect both viability and functionality, which constitutes an economic burden on the manufacturers of probiotic supplements who need to guarantee both viable number and functionality. Using both culture-dependant and independent techniques, this thesis shows that the manufacturing processes of tabletting induces a loss of viability of the Lab4® probiotic consortium in a control formulation. However, using in vitro and cell-based models, this piece of work has shown that the tabletting manufacturing processes does not affect some of the desirable functionalities of the probiotic when compared to the un-processed, control formulation. Pressure-dependant studies subsequently highlighted the causation between tablet compaction pressure and bacterial viability. Following this, optimisation work to improve tabletability and reduce the required compaction pressure was undertaken utilising both machining and formulation parameters. Results showed that optimisation of the control formulation and machining parameters were able to elicit greater bacterial recovery values without compromising on tablet integrity. The results from this Eng.D. can be seen as highly pertinent to the successful design and production of probiotic solid dosage formats, especially tablets. The results from which highlight the impact of tablet manufacturing methods on probiotic viability and functionality, therefore can be utilised to improve the probiotic product whilst also reducing costs through a reduced need to have large overages in bacterial additions to account for the previous losses that occur during tabletting. |
|---|---|
| Keywords: |
probiotic; tabletting; nutraceuticals; oral solid dose; functionality; viability; bacteria |
| College: |
Faculty of Science and Engineering |